Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J A Child

Showing results (91-100 of 126) with videos related to

Pageof 13
Sort By:
British Journal of Haematology|February 5, 1998
B-lymphocyte suppression in multiple myeloma is a reversible phenomenon specific to normal B-cell progenitors and plasma cell precursorsA C Rawstron, F E Davies, R G Owen, et al.
The Journal of Pathology|September 1, 1986
Cluster differentiation antigen expression, proliferative activity and clinical stage in centroblastic centrocytic lymphomasJ M Williamson, I Grigor, M E Smith, et al.
British Journal of Haematology|March 23, 1999
Development of an EORTC questionnaire module to be used in health-related quality-of-life assessment for patients with multiple myeloma. European Organization for Research and Treatment of Cancer Study Group on Quality of LifeM L Stead, J M Brown, G Velikova, et al.
Journal of Clinical Pathology|August 1, 1996
Assessment of IgH PCR strategies in multiple myelomaR G Owen, R J Johnson, A C Rawstron, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1994
ChlVPP/PABlOE and radiotherapy in advanced Hodgkin's disease. The Central Lymphoma GroupM H Cullen, N S Stuart, C Woodroffe, et al.
British Journal of Haematology|February 13, 2001
Interleukin 6, tumour necrosis factor alpha and lymphotoxin alpha polymorphisms in monoclonal gammopathy of uncertain significance and multiple myelomaA M Dring, F E Davies, S J Rollinson, et al.
Biochemical Society Transactions|May 30, 2003
Polymorphisms in Toll-like receptor 4 and the systemic inflammatory response syndromeN J A Child, I A Yang, M C K Pulletz, et al.
American Journal of Clinical Pathology|September 14, 2001
Waldenström macroglobulinemia. Development of diagnostic criteria and identification of prognostic factorsR G Owen, S L Barrans, S J Richards, et al.
Hematological Oncology|July 1, 1991
Twin-track studies of ifosfamide and mitoxantrone (I-M) in recurrent high grade non-Hodgkin's lymphoma and Hodgkin's disease. Yorkshire Regional Lymphoma and Central Lymphoma GroupsJ A Child, A V Simmons, D L Barnard, et al.
Leukemia & Lymphoma|April 7, 2000
FLUDAP: salvage chemotherapy for relapsed/refractory aggressive non-Hodgkin's lymphomaJ A Child, S A Johnson, S Rule, et al.
Pageof 13

Showing results (91-100 of 126) with videos related to

Sort By:
Pageof 13
British Journal of Haematology|February 5, 1998
B-lymphocyte suppression in multiple myeloma is a reversible phenomenon specific to normal B-cell progenitors and plasma cell precursorsA C Rawstron, F E Davies, R G Owen, et al.
The Journal of Pathology|September 1, 1986
Cluster differentiation antigen expression, proliferative activity and clinical stage in centroblastic centrocytic lymphomasJ M Williamson, I Grigor, M E Smith, et al.
British Journal of Haematology|March 23, 1999
Development of an EORTC questionnaire module to be used in health-related quality-of-life assessment for patients with multiple myeloma. European Organization for Research and Treatment of Cancer Study Group on Quality of LifeM L Stead, J M Brown, G Velikova, et al.
Journal of Clinical Pathology|August 1, 1996
Assessment of IgH PCR strategies in multiple myelomaR G Owen, R J Johnson, A C Rawstron, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1994
ChlVPP/PABlOE and radiotherapy in advanced Hodgkin's disease. The Central Lymphoma GroupM H Cullen, N S Stuart, C Woodroffe, et al.
British Journal of Haematology|February 13, 2001
Interleukin 6, tumour necrosis factor alpha and lymphotoxin alpha polymorphisms in monoclonal gammopathy of uncertain significance and multiple myelomaA M Dring, F E Davies, S J Rollinson, et al.
Biochemical Society Transactions|May 30, 2003
Polymorphisms in Toll-like receptor 4 and the systemic inflammatory response syndromeN J A Child, I A Yang, M C K Pulletz, et al.
American Journal of Clinical Pathology|September 14, 2001
Waldenström macroglobulinemia. Development of diagnostic criteria and identification of prognostic factorsR G Owen, S L Barrans, S J Richards, et al.
Hematological Oncology|July 1, 1991
Twin-track studies of ifosfamide and mitoxantrone (I-M) in recurrent high grade non-Hodgkin's lymphoma and Hodgkin's disease. Yorkshire Regional Lymphoma and Central Lymphoma GroupsJ A Child, A V Simmons, D L Barnard, et al.
Leukemia & Lymphoma|April 7, 2000
FLUDAP: salvage chemotherapy for relapsed/refractory aggressive non-Hodgkin's lymphomaJ A Child, S A Johnson, S Rule, et al.
Pageof 13